CO6781464A2 - Péptidos del veneno de escorpión rhopalorus junceus y composición farmacéutica - Google Patents
Péptidos del veneno de escorpión rhopalorus junceus y composición farmacéuticaInfo
- Publication number
- CO6781464A2 CO6781464A2 CO13105491A CO13105491A CO6781464A2 CO 6781464 A2 CO6781464 A2 CO 6781464A2 CO 13105491 A CO13105491 A CO 13105491A CO 13105491 A CO13105491 A CO 13105491A CO 6781464 A2 CO6781464 A2 CO 6781464A2
- Authority
- CO
- Colombia
- Prior art keywords
- junceus
- rhopalorus
- scorpion venom
- pharmaceutical composition
- venom peptides
- Prior art date
Links
- 239000002795 scorpion venom Substances 0.000 title abstract 2
- 101000761020 Dinoponera quadriceps Poneritoxin Proteins 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 241001050861 Rhopalurus junceus Species 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 230000001093 anti-cancer Effects 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 235000014633 carbohydrates Nutrition 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 150000002500 ions Chemical class 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000000771 oncological effect Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
- C07K14/43522—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/646—Arachnids, e.g. spiders, scorpions, ticks or mites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Insects & Arthropods (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2010000186A CU24055B1 (es) | 2010-09-27 | 2010-09-27 | Composiciones farmacéuticas de veneno de escorpión rhopalurus junceus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6781464A2 true CO6781464A2 (es) | 2013-10-31 |
Family
ID=45566782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO13105491A CO6781464A2 (es) | 2010-09-27 | 2013-04-25 | Péptidos del veneno de escorpión rhopalorus junceus y composición farmacéutica |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP2623111A2 (enExample) |
| JP (1) | JP2013542196A (enExample) |
| KR (1) | KR20140041381A (enExample) |
| CN (1) | CN103200951A (enExample) |
| AP (1) | AP2013006811A0 (enExample) |
| AR (1) | AR083117A1 (enExample) |
| AU (1) | AU2011307691A1 (enExample) |
| BR (1) | BR112013007198A2 (enExample) |
| CA (1) | CA2812841A1 (enExample) |
| CO (1) | CO6781464A2 (enExample) |
| CU (1) | CU24055B1 (enExample) |
| EC (1) | ECSP13012595A (enExample) |
| IL (1) | IL225577A0 (enExample) |
| MX (1) | MX360726B (enExample) |
| RU (1) | RU2563348C2 (enExample) |
| SG (1) | SG191708A1 (enExample) |
| WO (1) | WO2012041261A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103074304B (zh) * | 2013-01-28 | 2016-01-13 | 江苏健安生物科技有限公司 | 高水平人二倍体细胞培养水痘-带状疱疹疫苗病毒方法 |
| MX2019000570A (es) * | 2018-12-19 | 2020-08-13 | Centro De Investig Biologicas Del Noroeste S C | Composición homeopatica a base de veneno de escorpión rhopalurus junceus y su uso en acuicultura. |
| EP4267251A4 (en) * | 2020-12-22 | 2024-12-18 | Preveceutical Medical Inc. | CYCLIC PEPTIDES AND USES THEREOF |
| CN113384682B (zh) * | 2021-05-31 | 2023-07-04 | 南方医科大学 | 蝎毒多肽Smp43在制备抗肿瘤药物的应用 |
| CN117069800B (zh) * | 2023-10-16 | 2023-12-12 | 山东省食品药品检验研究院 | 一种鉴别东亚钳蝎的特征多肽及其应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1030229C (zh) | 1991-12-16 | 1995-11-08 | 山东省蒙阴县酒厂 | 全蝎酒的制作方法 |
| CN1076858A (zh) | 1993-03-24 | 1993-10-06 | 王强华 | 熊胆全蝎酒及其制备工艺 |
| CU22413A1 (es) | 1994-01-11 | 1996-01-31 | Composicion antitumoral | |
| US5905027A (en) | 1995-12-27 | 1999-05-18 | Uab Research Foundation | Method of diagnosing and treating gliomas |
| FR2745004B1 (fr) * | 1996-02-16 | 1998-03-27 | Rhone Poulenc Agrochimie | Peptide antibacterien et antifongique |
| US6168651B1 (en) | 1998-10-08 | 2001-01-02 | Donaldson Company, Inc. | Filter assembly with shaped adsorbent article; and devices and methods of use |
| CN1279088A (zh) | 1999-06-25 | 2001-01-10 | 谷令旗 | 一种治疗肝癌药剂的制备方法 |
| CN1265901A (zh) | 2000-01-26 | 2000-09-13 | 徐忠廷 | 一种抗癌中药丸剂 |
| CN1316249A (zh) | 2001-04-04 | 2001-10-10 | 李滋星 | 全蝎活性营养液 |
| CN1157215C (zh) | 2001-07-30 | 2004-07-14 | 张官锁 | 一种治疗癌症的中药组合物 |
| CN1325514C (zh) * | 2001-09-30 | 2007-07-11 | 沈阳药科大学 | 蝎镇痛抗肿瘤缬精甘肽及获得方法 |
| CN100465272C (zh) * | 2002-01-18 | 2009-03-04 | 中国科学院上海有机化学研究所 | 重组东亚马氏钳蝎毒rBmKaIT1的基因工程 |
| WO2003101475A1 (en) * | 2002-05-31 | 2003-12-11 | Transmolecular Inc. | Treatment of cell proliferative disorders with chlorotoxin |
| CN1256971C (zh) | 2002-08-12 | 2006-05-24 | 徐继康 | 一种用于治疗肿瘤的中药胶囊 |
| US8097284B2 (en) * | 2007-11-13 | 2012-01-17 | Arthur Mikaelian | Polarized scorpion venom solution and a method for making polarized scorpion venom solution |
-
2010
- 2010-09-27 CU CU2010000186A patent/CU24055B1/es not_active IP Right Cessation
-
2011
- 2011-09-27 AP AP2013006811A patent/AP2013006811A0/xx unknown
- 2011-09-27 MX MX2013003545A patent/MX360726B/es active IP Right Grant
- 2011-09-27 AR ARP110103520A patent/AR083117A1/es not_active Application Discontinuation
- 2011-09-27 EP EP11815845.0A patent/EP2623111A2/en not_active Withdrawn
- 2011-09-27 JP JP2013530559A patent/JP2013542196A/ja active Pending
- 2011-09-27 RU RU2013119431/10A patent/RU2563348C2/ru active IP Right Revival
- 2011-09-27 KR KR1020137010868A patent/KR20140041381A/ko not_active Ceased
- 2011-09-27 SG SG2013022850A patent/SG191708A1/en unknown
- 2011-09-27 CA CA2812841A patent/CA2812841A1/en not_active Abandoned
- 2011-09-27 CN CN2011800541685A patent/CN103200951A/zh active Pending
- 2011-09-27 BR BR112013007198A patent/BR112013007198A2/pt not_active IP Right Cessation
- 2011-09-27 WO PCT/CU2011/000006 patent/WO2012041261A2/es not_active Ceased
- 2011-09-27 AU AU2011307691A patent/AU2011307691A1/en not_active Abandoned
-
2013
- 2013-04-04 IL IL225577A patent/IL225577A0/en unknown
- 2013-04-25 CO CO13105491A patent/CO6781464A2/es not_active Application Discontinuation
- 2013-04-29 EC ECSP13012595 patent/ECSP13012595A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011307691A1 (en) | 2013-05-02 |
| JP2013542196A (ja) | 2013-11-21 |
| KR20140041381A (ko) | 2014-04-04 |
| AP2013006811A0 (en) | 2013-04-30 |
| EP2623111A2 (en) | 2013-08-07 |
| SG191708A1 (en) | 2013-08-30 |
| CN103200951A (zh) | 2013-07-10 |
| ECSP13012595A (es) | 2014-11-28 |
| RU2563348C2 (ru) | 2015-09-20 |
| CA2812841A1 (en) | 2012-04-05 |
| CU24055B1 (es) | 2014-12-26 |
| WO2012041261A3 (es) | 2012-11-22 |
| WO2012041261A2 (es) | 2012-04-05 |
| AR083117A1 (es) | 2013-01-30 |
| IL225577A0 (en) | 2013-06-27 |
| CU20100186A7 (es) | 2012-06-21 |
| BR112013007198A2 (pt) | 2016-06-14 |
| MX2013003545A (es) | 2013-11-04 |
| MX360726B (es) | 2018-11-13 |
| RU2013119431A (ru) | 2014-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015009228A8 (pt) | Formulação farmacêutica líquida estéril e forma de dosagem intraocular oftálmica líquida estéril para injeção | |
| MX349992B (es) | Composiciones de alta concentracion de alfa-glucosidasa para el tratamiento de la enfermedad de pompe. | |
| MX2013012725A (es) | FORMULACION PARA ANTICUERPO ANTI -A4ß7. | |
| BR112013019026A2 (pt) | formulações farmacêuticas incluindo um composto amina | |
| BR112013000255A2 (pt) | ácidos hidróxifenil-hexinoicos substituídos por ariloxialquileno, método para preparação dos mesmos e seu uso dos mesmos como um medicamento | |
| BR112014009146A8 (pt) | formulações de etanercepte estabilizadas com aminoácidos | |
| BR112012023421A2 (pt) | composição farmacêutica para tratamento de aumento de pressão intraocular | |
| CO6640206A2 (es) | Formulación farmaceútica de una solución acuosa de un bufer de ácido glutámico y un anticuerpo | |
| BR112012022223A2 (pt) | formulações de proteína concentrada e usos das mesmas | |
| BR112015018838A2 (pt) | estabilidade melhorada de novas composições líquidas | |
| BR112015008297A2 (pt) | antagonistas de mglu2/3 para o tratamento de distúrbios autistas | |
| CO6710913A2 (es) | Uso de ácido lipasa lisosomal para tratar la deficiencia de ácido lipasa lisosomal en pacientes | |
| BR112013003068A2 (pt) | combinação do composto glyt1 com antipsicóticos | |
| CO6781464A2 (es) | Péptidos del veneno de escorpión rhopalorus junceus y composición farmacéutica | |
| PE20150190A1 (es) | Formulacion farmaceutica | |
| PE20130379A1 (es) | Metodos para el tratamiento de las ulceras del pie diabetico | |
| ECSP14013200A (es) | Una nueva composición terapéutica que contiene apomorfina como principio activo | |
| BR112014012459A2 (pt) | 2h-indazóis como antagonistas do receptor de ep2 | |
| MX2016011290A (es) | Composiciones de ester de colina de acido lipoico y metodos de uso. | |
| BR112015030431A2 (pt) | formulação de liberação modificada | |
| MX2014003334A (es) | Derivados de tio novedosos que tienen lactamas como potentes inhibidores de hdac y sus usos como medicamentos. | |
| UY33417A (es) | Formulación que contiene acido azelaico con adición de pigmento | |
| BR112014009760A2 (pt) | análogos de ácido siálico, seu uso e composição farmacêutica e composição farmacêutica de liberação sustentada os compreendendo | |
| ES2403549R1 (es) | Co-cristales de agomelatina con formadores de co-cristales | |
| MX373378B (es) | Una composicion farmaceutica soluble en agua que comprende al menos una sustancia terapeuticamente activa de caracteristicas hidrofobicas y al menos un compuesto seleccionado entre los sialoglicoesfingolipidos, los glicoesfingolipidos o una mezcla de sialoglicoesfingolipidos y glicoesfingolipidos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |